venBio Partners LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001776382 · Show all filings

Period: Q3 2022 (← Previous) (Next →)

Filing Date: Nov 14, 2022

Total Value: $432M (100.0% shares, 0.0% debt)

Holdings (8)

VTYX VENTYX BIOSCIENCES INC 40.5%

Value $175M Shares 5,011,536 Est. Cost $18.95 Unrealized +16.8%

ALXO ALX ONCOLOGY HLDGS INC 21.5%

Value $92.83M Shares 9,699,925 Est. Cost $39.31 Unrealized -70.3%

— CINCOR PHARMA INC 14.1%

Value $61.12M Shares 1,862,256 Est. Cost $17.64 Unrealized —

HRMY HARMONY BIOSCIENCES HLDGS IN 11.5%

Value $49.86M Shares 1,125,673 Est. Cost $36.46 Unrealized +33.8%

— AKERO THERAPEUTICS INC 4.7%

Value $20.31M Shares 596,483 Est. Cost $19.15 Unrealized —

PHVS PHARVARIS N V 4.1%

Value $17.62M Shares 2,296,710 Est. Cost $31.46 Unrealized -50.4%

— IMPEL PHARMACEUTICALS INC 3.1%

Value $13.44M Shares 2,759,791 Est. Cost $8.85 Unrealized —

— ELEVATION ONCOLOGY INC 0.5%

Value $2.109M Shares 1,866,339 Est. Cost $13.57 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
VTYX	VENTYX BIOSCIENCES INC	5,011,536	$175M	40.5%	$18.95	+16.8%	COM	92332V107
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$92.83M	21.5%	$39.31	-70.3%	COM	00166B105
—	CINCOR PHARMA INC	1,862,256	$61.12M	14.1%	$17.64	—	COM	17240Y109
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,125,673	$49.86M	11.5%	$36.46	+33.8%	COM	413197104
—	AKERO THERAPEUTICS INC	596,483	$20.31M	4.7%	$19.15	—	COM	00973Y108
PHVS	PHARVARIS N V	2,296,710	$17.62M	4.1%	$31.46	-50.4%	COM	N69605108
—	IMPEL PHARMACEUTICALS INC	2,759,791	$13.44M	3.1%	$8.85	—	COM	45258K109
—	ELEVATION ONCOLOGY INC	1,866,339	$2.109M	0.5%	$13.57	—	COM	28623U101